PGR and cancer: Overall, 52.8 % were ER+/PR+, 13.1 % ER−/PR−, and 8.2 % ER+/PR−; among invasive cancers (n = 277), 62.5 % were ER+/PR+ and 15.2 %, ER−/PR− (Table 2).